Premium
O1‐04‐01: Multicentre phase 3 trial on florbetaben for beta‐amyloid brain PET in Alzheimer's disease
Author(s) -
Sabbagh Marwan,
Seibyl John,
Akatsu Hiroyasu,
Ouchi Yasoumi,
Beach Thomas,
Charny Albert,
Barthel Henryk,
Senda Kohei,
Muryama Shigeo,
Iishi Kenji,
Leverenz James,
Ghetti Bernardino,
Ironside James,
Roth Katrin,
Hoffmann Anja,
SchulzSchaeffer Walter,
Reininger Cornelia,
Sabri Osama
Publication year - 2012
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2012.05.220
Subject(s) - medicine , amyloid (mycology) , biomarker , pathology , nuclear medicine , amyloid beta , disease , biology , biochemistry
maximal HR (220-age), 3) respiratory-exchange-ratio (RER)>1.1, and 4) blood lactate>8.0mmol/l. Results: Twenty-six MCI patients (77%) and 16 controls (76%) achieved VO 2max. No difference was found in VO 2max (22.97 6 4.39 vs. 22.49 6 4.69 ml/kg/min), CI (6.06 6 1.08 vs. 6.05 6 1.12 l/min/m 2), peak HR (160 6 15 vs. 160 6 13 BPM), and SV (75.7 6 22.4 vs. 70.5 6 14.2 ml) between groups. However, MCI patients exhibited higher SBP (203 6 27 vs. 185 6 29 mmHg, p<.05) and DBP (89 6 18 vs. 77 6 12 mmHg, p<.05) at the peak work load. Conclusions: With appropriate medical supervision, MCI patients can safely perform maximal exercise testing similar to normal older adults. The elevated blood pressure response in MCI during exercise suggests a failure of baroreflex resetting during exercise and/or increased arterial stiffness.